Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

November 17, 2020November 18, 2020

3 FAP Therapies Win 2020 Prix Galien USA Awards for Best Biotechnology Product

News

Three recently approved therapies for treating familial amyloid polyneuropathy (FAP), also known as hereditary transthyretin amyloidosis with polyneuropathy, have won their developers Best Biotechnology Product honors in the 2020 ... Read more

September 1, 2020September 1, 2020

Vyndaqel Remains Safe After 3 Years of Treatment, Analysis Shows

News

Vyndaqel (tafamidis meglumine) remains safe after more than three years of treatment in patients with familial amyloid polyneuropathy (FAP), with no new safety concerns raised, according to an early ... Read more

March 10, 2020March 10, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

December 10, 2019December 10, 2019

Diuretics to Treat Blood Pressure May Stop Proteins from Clumping, Early Study Suggests

News

Two FDA-approved treatments for high blood pressure, diuretics called indapamide and hydrochlorothiazide, might also treat diseases associated with amyloid deposits, such as familial amyloid polyneuropathy (FAP), a study suggests. ... Read more

December 3, 2019December 3, 2019

Alnylam Opens ‘Advocacy for Impact’ Grant Program Supporting FAP, Like Patient Groups

News

Alnylam Pharmaceuticals has opened its second annual competitive grants program, supporting patient advocacy projects worldwide that aim to address the unmet and diverse needs of ATTR amyloidosis, a group of ... Read more

April 16, 2019April 16, 2019

Age-related Changes in TTR Gene Expression May Explain Disease Differences Within Families, Study Suggests

News

Variability in the onset and penetrance of TTR-related amyloidosis (ATTR) among members of the same family may be linked to the expression of different copies of the TTR gene ... Read more

February 19, 2019February 19, 2019

FAP More Diverse Than Previously Believed, Review Study Contends

News

A review of 542 cases of hereditary transthyretin amyloid polyneuropathy (ATTR-PN) from more than 100 countries suggests that the clinical symptoms and geographical occurrence of the disease is more ... Read more

January 22, 2019January 22, 2019

Heart Problems Are Top Cause of Death for FAP Patients Who Had Liver Transplant, Study Says

News

Cardiac problems are the leading cause of death among transthyretin familial amyloid polyneuropathy (ATTR, also called FAP) patients who have had a liver transplant, according to a retrospective longitudinal ... Read more

January 8, 2019January 8, 2019

Vyndaqel May Help Halt Neurological Disease Progression in Patients With Val30Met Mutation, Study Reveals

News

Early diagnosis and prompt treatment with Vyndaqel (tafamidis) may help halt neurological disease progression in familial amyloid polyneuropathy (FAP) patients who are positive for the Val30Met mutation, clinical analyses of ... Read more

September 20, 2018September 20, 2018

News

Tests used to assess sensitivity to heat and cold may help diagnose patients with familial amyloid polyneuropathy (FAP) earlier as well as track their improvement after liver transplant, a ... Read more